Artivion (NYSE:AORT) Price Target Raised to $51.00 at Canaccord Genuity Group

Artivion (NYSE:AORT) had its target price boosted by Canaccord Genuity Group from $50.00 to $51.00 in a report released on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Stifel Nicolaus lifted their price objective on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. JMP Securities upped their target price on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Citizens Jmp raised their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday. Finally, Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Trading Down 5.6%

NYSE:AORT traded down $2.68 during trading hours on Friday, reaching $44.82. 582,541 shares of the stock were exchanged, compared to its average volume of 433,923. Artivion has a twelve month low of $21.97 and a twelve month high of $47.69. The business has a 50-day moving average of $42.44 and a two-hundred day moving average of $35.40. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -106.72 and a beta of 1.65. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $113.39 million during the quarter, compared to analysts’ expectations of $110.71 million. The firm’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Activity

In related news, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the transaction, the senior vice president owned 64,200 shares of the company’s stock, valued at $2,826,084. This represents a 22.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of Artivion stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the sale, the chief executive officer directly owned 852,783 shares of the company’s stock, valued at $36,089,776.56. This trade represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 74,858 shares of company stock valued at $3,250,129 over the last quarter. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue increased its stake in Artivion by 1.8% in the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock valued at $985,000 after purchasing an additional 414 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Artivion by 6.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after buying an additional 477 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Artivion by 5.8% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company’s stock valued at $395,000 after buying an additional 510 shares during the last quarter. Franklin Resources Inc. raised its stake in Artivion by 1.9% during the 2nd quarter. Franklin Resources Inc. now owns 29,263 shares of the company’s stock worth $910,000 after acquiring an additional 533 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.